UK markets open in 47 minutes

Hikma Pharmaceuticals PLC (HKMPY)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
49.000.00 (0.00%)
At close: 04:00PM EDT

Hikma Pharmaceuticals PLC

1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees9,100

Key executives

NameTitlePayExercisedYear born
Engineer Said Samih Taleb DarwazahExecutive Chairman2.8MN/A1957
Mr. Riad Ali MishlawiCEO & Director1.1MN/A1964
Mr. Mazen Samih Taleb DarwazahExecutive Vice Chairman & President of MENA2.3MN/A1958
Mr. Khalid Waleed Hosny Al NabilsiChief Financial OfficerN/AN/A1972
Patricia BousfieldChief Information OfficerN/AN/AN/A
Mr. Guy FeatherstoneAssociate Director of Investor RelationsN/AN/AN/A
Mr. Samuel ParkGeneral CounselN/AN/AN/A
Mr. Bassam Wael Rushdi Kanaan CFA, CPAExecutive Vice President of Corporate Development and M&AN/AN/A1965
Mr. Hussein Omar ArkhaghaChief People OfficerN/AN/AN/A
Ms. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Corporate governance

Hikma Pharmaceuticals PLC’s ISS governance QualityScore as of 1 July 2024 is 3. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.